3C protease of enterovirus 68: Structure-based design of michael acceptor inhibitors and their broad-spectrum antiviral effects against picornaviruses

Journal of Virology

Volumn 87, Issue 8, 2013, Pages 4339-4351

  Tan, Jinzhi ^a   George, Shyla ^a   Kusov, Yuri ^a   Perbandt, Markus ^a   Anemüller, Stefan ^a   Mesters, Jeroen R ^a   Norder, Helene ^b   Coutard, Bruno ^c   Lacroix, Céline ^d   Leyssen, Pieter ^d   Neyts, Johan ^d   Hilgenfeld, Rolf ^a,e  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c AIX MARSEILLE UNIVERSITY   (France)

^d REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^e SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CHYMOTRYPSIN; CYSTEINE; CYSTEINE PROTEINASE; ENVIROXIME; GLUTAMIC ACID; HISTIDINE; NICORANDIL; SG 74; SG 81; SG 82; SG 83; SG 84; SG 85; SG 98; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CELL CULTURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CRYSTAL STRUCTURE; ECHO VIRUS; ENTEROVIRUS; ENTEROVIRUS 68; ENZYME PURIFICATION; ENZYME SPECIFICITY; ENZYME STRUCTURE; HUMAN; HUMAN CELL; MEDIAN EFFECTIVE CONCENTRATION; NONHUMAN; PHYLOGENY; PICORNAVIRUS; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; REPLICON; RHINOVIRUS; SEROTYPE; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION;

ANTIVIRAL AGENTS; CELL LINE; CRYSTALLOGRAPHY, X-RAY; CYSTEINE ENDOPEPTIDASES; DESIGNER DRUGS; DRUG DESIGN; HUMANS; MICROBIAL SENSITIVITY TESTS; PICORNAVIRIDAE; PROTEASE INHIBITORS; PROTEIN CONFORMATION; VIRAL PROTEINS;

ENTEROVIRUS; HUMAN ECHOVIRUS 11; HUMAN ENTEROVIRUS 68; HUMAN RHINOVIRUS 14; POLIOVIRUS; RHINOVIRUS;

EID: 84875769296     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01123-12     Document Type: Article

References (43)

1. Norder H, De Palma AM, Selisko B, Costenaro L, Papageorgiou N, Arnand C, Coutard B, Lantez V, De Lamballerie X, Baronti C, Solà M, Tan J, Neyts J, Canard B, Coll M, Gorbalenya AE, Hilgenfeld R. 2011. Picornavirus nonstructural proteins as targets for new antivirals with broad activity. Antivir. Res. 89:204-218.
2. Pallansch M, Roos R. 2007. Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses, p 840-893. In Knipe DM, PM Howley (ed), Fields virology, 5th ed. Lippincott/Williams&Wilkins, Philadelphia, PA.
3. Yang F, Ren L, Xiong Z, Li J, Xiao Y, Zhao R, He Y, Bu G, Zhou S, Wang J, Qi J. 2009. Enterovirus 71 outbreak in the People's Republic of China in 2008. J. Clin. Microbiol. 47:2351-2352.
4. Collett MS, Neyts J, Modlin JF. 2008. A case for developing antiviral drugs against polio. Antivir. Res. 79:179-187.
5. Hilgenfeld R. 2010. Structure-based antivirals for emerging and neglected RNA viruses: an emerging field for medicinal chemistry in academia. Future Med. Chem. 2:1061-1067.
6. Steuber H, Hilgenfeld R. 2010. Recent advances in targeting viral proteases for the discovery of novel antivirals. Curr. Top. Med. Chem. 23: 323-345.
7. Hayden FG, Turner RB, Gwaltney JM, Chi-Burris K, Gersten M, Hsyu P, Patick AK, Smith GJ, III, Zalman LS. 2003. Phase II, randomized, double-blind, placebo-controlled studies of rupintrivir nasal spray 2-percent suspension for prevention and treatment of experimentally induced rhinovirus colds in healthy volunteers. Antimicrob. Agents Chemother. 47:3907-3916.
8. Matthews DA, Dragovich PS, Webber SE, Fuhrman SA, Patick AK, Zalman LS, Hendrickson TF, Love RA, Prins TJ, Marakovits JT, Zhou R, Tikhe J, Ford CE, Meador JW, Ferre RA, Brown EL, Binford SL, Brothers MA, DeLisle DM, Worland ST. 1999. Structure-assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes. Proc. Natl. Acad. Sci. U. S. A. 96:11000-11007.
9. Dragovich PS, Prins TJ, Zhou R, Webber SE, Marakovits JT, Fuhrman SA, Patick AK, Matthews DA, Lee CA, Ford CE, Burke BJ, Rejto PA, Hendrickson TF, Tuntland T, Brown EL, Meador JW, Ferre RA, Harr JEV, Kosa MB, Worland ST. 1999. Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements. J. Med. Chem. 42:1213-1224.
10. Anand K, Ziebuhr J, Wadhwani P, Mesters JR, Hilgenfeld R. 2003. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 300:1763-1767.
11. Kuo CJ, Shie JJ, Fang JM, Yen GR, Hsu JTA, Liu HG, Tseng SN, Chang SC, Lee CY, Shih SR, Liang PH. 2008. Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents. Bioorg. Med. Chem. 16:7388-7398.
12. Lee CC, Kuo CJ, Ko TP, Hsu MF, Tsui YC, Chang SC, Yang S, Chen SJ, Chen HC, Hsu MC, Shih SR, Liang PH, Wang AH. 2009. Structural basis of inhibition specificities of 3C and 3C-like proteases by zinccoordinating and peptidomimetic compounds. J. Biol. Chem. 284:7646-7655.
13. Lee ES, Lee WG, Yun SH, Rho SH, Im I, Yang ST, Sellamuthu S, Lee YJ, Kwon SJ, Park OK, Jeon ES, Park WJ, Kim YC. 2007. Development of potent inhibitors of the coxsackievirus 3C protease. Biochem. Biophys. Res. Commun. 358:7-11.
14. Yang H, Xie W, Xue X, Yang K, Ma J, Liang W, Zhao Q, Zhou Z, Pei D, Ziebuhr J, Hilgenfeld R, Yuen KY, Wong L, Gao G, Chen S, Chen Z, Ma D, Bartlam M, Rao Z. 2005. Design of wide-spectrum inhibitors targeting coronavirus main proteases. PLoS Biol. 3:e324. doi:10.1371 /journal.pbio.0030324.
15. Mou K, Xu B, Ma C, Yang X, Zou X, Lü Y, Xu P. 2008. Novel CADD-based peptidyl vinyl ester derivatives as potential proteasome inhibitors. Bioorg. Med. Chem. Lett. 18:2198-2202.
16. Berrow NS, Alderton D, Sainsbury S, Nettleship J, Assenberg R, Rahman N, Stuart DI, Owens RJ. 2007. A versatile ligation-independent cloning method for high-throughput expression screening applications. Nucleic Acids Res. 35:e45.
17. Leslie AGW, Powell HR. 2007. Processing diffraction data with MOSFLM, p 41-51. In Read RJ, Sussmann JL (ed), Evolving methods for macromolecular crystallography. Springer, Berlin, Germany.
18. Evans P. 2006. Scaling and assessment of data quality. Acta Crystallogr. D Biol. Crystallogr. 62:72-82.
19. Collaborative Computational Project No. 4. 1994. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. Sect.DBiol. Crystallogr. 50:760-763.
20. Rossmann MG. 1990. The molecular replacement method. Acta Crystallogr. A Foundations Crystallogr. 46:73-82.
21. Vagin A, Teplyakov A. 1997. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30:1022-1025.
22. Emsley P, Cowtan K. 2004. Coot: model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. D 60:2126-2132.
23. Murshudov GN, Vagin AA, Dodson EJ. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53:240-255.
24. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. 1993. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26:283-291.
25. Vaguine AA, Richelle J, Wodak SJ. 1999. SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. Acta Crystallogr. D Biol. Crystallogr. 55:191-205.
26. Tan J, Verschueren KH, Anand K, Shen J, Yang M, Xu Y, Rao Z, Bigalke J, Heisen B, Mesters JR, Chen K, Shen X, Jiang H, Hilgenfeld R. 2005. pH-dependent conformational flexibility of the SARS-CoV main proteinase (Mpro) dimer: molecular dynamics simulations and multiple X-ray structure analyses. J. Mol. Biol. 354:25-40.
27. Wilkinson GN. 1961. Statistical estimations in enzyme kinetics, Biochem. J. 80:324-332.
28. Verschueren KHG, Pumpor K, Anemüller S, Chen S, Mesters JR, Hilgenfeld R. 2008. A structural view of the inactivation of the SARScoronavirus main proteinase by benzotriazole esters. Chem. Biol. 15:597-606.
29. Meara JP, Rich DH. 1995. Measurement of individual rate constants of irreversible inhibition of a cysteine proteinase by an epoxysuccinyl inhibitor. Bioorg. Med. Chem. Lett. 5:2277-2282.
30. Schultz DE, Honda M, Whetter LE, McKnight KL, Lemon SM. 1996. Mutations within the 5' nontranslated RNA of cell culture-adapted hepatitis A virus which enhance cap-independent translation in cultured African green monkey cells. J. Virol. 70:1041-1049.
31. Andino R, Rieckhof GE, Achacoso PL, Baltimore D. 1993. Poliovirus RNA synthesis utilizes an RNP complex formed around the 5= end of viral RNA. EMBO J. 12:3587-3598.
32. Gauss-Müller V, Kusov Y. 2002. Replication of a hepatitis A virus replicon detected by genetic recombination in vivo. J. Gen. Virol. 83:2183-2192.
33. Mosimann SC, Cherney MM, Sia S, Plotch S, James MN. 1997. Refined X-ray crystallographic structure of the poliovirus 3C gene product. J. Mol. Biol. 273:1032-1047.
34. Costenaro L, Kaczmarska Z, Arnan C, Janowski R, Coutard B, Sola M, Gorbalenya AE, Norder H, Canard B, Coll M. 2011. Structural basis of antiviral inhibition of the main protease, 3C, from enterovirus 93. J. Virol. 85:10764-10773.
35. Lu GW, Qi JX, Chen ZJ, Xu X, Gao F, Lin DZ, Qian WK, Liu H, Jiang HL, Yan JH, Gao GF. 2011. Enterovirus 71 and coxsackievirus A16 3C proteases: binding to rupintrivir and their substrates and anti-hand, foot, and mouth disease virus drug design. J. Virol. 85:10319-10331.
36. Bergmann EM, Mosimann SC, Chernaia MM, Malcolm BA, James MN. 1997. The refined crystal structure of the 3C gene product from hepatitis A virus: specific proteinase activity and RNA recognition. J. Virol. 71:2436-2448.
37. Birtley JR, Knox SR, Jaulent AM, Brick P, Leatherbarrow RJ, Curry S. 2005. Crystal structure of foot-and-mouth-disease virus 3C protease. J. Biol. Chem. 280:11520-11527.
38. Brandl M, Weiss MS, Sühnel J, Hilgenfeld R. 2001. C-H...π interactions in proteins. J. Mol. Biol. 307:357-377.
39. Weiss MS, Brandl M, Sühnel J, Pal D, Hilgenfeld R. 2001. More hydrogen bonds for the (structural) biologist. Trends Biochem. Sci. 26: 521-523.
40. Blomqvist S, Savolainen C, Råman L, Roivainen M, Hovi T. 2002. Human rhinovirus 87 and enterovirus 68 represent a unique serotype with rhinovirus and enterovirus properties. J. Clin. Microbiol. 40:4218-4223.
41. Ishiko H, Miura R, Shimada Y, Hayashi A, Nakajima H, Yamazaki S, Takeda N. 2002. Human rhinovirus 87 identified as human enterovirus 68 by VP4-based molecular diagnosis. Intervirology 45:136-141.
42. Oberste MS, Maher K, Schnurr D, Flemister MR, Lovchik JC, Peters H, Sessions W, Kirk C, Chatterjee N, Fuller S, Hanauer JM, Pallansch MA. 2004. Enterovirus 68 is associated with respiratory illness and shares biological features with both the enteroviruses and the rhinoviruses. J. Gen. Virol. 85:2577-2584.
43. Matthews BW. 1968. Solvent content of protein crystals. J. Mol. Biol. 33:491-497.